Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Common Equity (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Common Equity for 4 consecutive years, with -$36.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 59.54% year-over-year to -$36.6 million, compared with a TTM value of -$36.6 million through Sep 2025, up 59.54%, and an annual FY2024 reading of -$97.3 million, up 1.96% over the prior year.
  • Common Equity was -$36.6 million for Q3 2025 at Atara Biotherapeutics, down from -$35.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $257.5 million in Q2 2022 and bottomed at -$110.9 million in Q2 2024.
  • Average Common Equity over 4 years is $12.9 million, with a median of -$36.6 million recorded in 2025.
  • The sharpest move saw Common Equity tumbled 1587.36% in 2024, then soared 68.39% in 2025.
  • Year by year, Common Equity stood at $126.6 million in 2022, then tumbled by 178.36% to -$99.2 million in 2023, then grew by 1.96% to -$97.3 million in 2024, then surged by 62.34% to -$36.6 million in 2025.
  • Business Quant data shows Common Equity for ATRA at -$36.6 million in Q3 2025, -$35.0 million in Q2 2025, and -$55.1 million in Q1 2025.